anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A vehicle for administering a drug comprises a thin body of resiliently flexible gelatinous material having a concave depression in at least one major surface thereof and shaped to enable it to be introduced into the parabuccal cavity to become adhered to the mucous membrane thereat by reason of the concave depression, the said material being impregnated with a drug which is effective when absorbed through the said mucous membrane.  The gelatinous material may have a glyco-gelatine, alginate, or resin basis.  In the case of a glyco-gelatine base, plasticisers and preservatives, e.g. b -naphthol, may be added.  The vehicle may be made by impregnating a solution or melt of the gelatinous material with an appropriate drug, followed by forming the impregnated solution or melt into the appropriate shape by moulding or by casting into strips, followed by punching or pressing.  Drugs specified include hormones, local anaesthetics, sympathomimetic amines, vaso-dilators, analgesics, antihistamines, diuretics, cardio-vascular reactants, muscle relaxants, ganglion blocking agents, barbiturates, oxytocin, substances acting on the parasympathetic system, alkaloids, glycosides, nitrites, analeptics, cyto-toxic agents, anticoagulants, vitamins, trace elements, antibiotics, and diagnostic agents, e.g. p-amino-hippuric acid.
A cosmetic composition for inhibiting skin aging comprising a liposome containing adenosine having anti-aging effects and a manufacturing method thereof are provided to maintain adenosine activity without activity loss or deterioration for a long period by using liposome, so that stability and percutaneous absorbability of the adenosine are improved. The cosmetic composition for inhibiting skin aging comprises the liposome containing 0.01-5.0% of adenosine having anti-aging effects, 1.0-10.0% of lecithin, 0.1-2.0% of ceramide, 0.1-5.0% of antioxidant, 0.1-20.0% of grape fruit seed extract and 0.1-50.0% of emulsion stabilization adjuvant. The antioxidant is selected from tocopherol derivatives including tocopheryl acetate; ascorbic acid derivatives including ascorbic acid; ubiquinone; idebenone; alpha-lipoic acid; BHT(butylated hydroxytoluene); and grape fruit extract. The emulsion stabilization adjuvant is selected from propylene glycol, butylenes glycol, glycerin, xylitol and natural polymer compound. The liposome is prepared by passing a mixture containing purified water, lecithin, ceramide, antioxidant, grape fruit seed extract and adenosine through a high pressure homogenizer. The cosmetic composition is formulated as skin lotion, nutrition lotion, nutrition cream, massage cream or nutrition essence.
The patient will undergo fecal microbiota transplant. The 600cc of donor stool will be transplanted by colonoscopy.
OBJECTIVE: Despite the publication of various national/international guidelines, several questions concerning the management of patients with asymptomatic (AsxCS) and symptomatic (SxCS) carotid stenosis remain unanswered. The aim of this international, multi-specialty, expert-based Delphi Consensus document was to address these issues to help clinicians make decisions when guidelines are unclear.
METHODS: Fourteen controversial topics were identified. A three-round Delphi Consensus process was performed including 61 experts. The aim of Round 1 was to investigate the differing views and opinions regarding these unresolved topics. In Round 2, clarifications were asked from each participant. In Round 3, the questionnaire was resent to all participants for their final vote. Consensus was reached when ≥75% of experts agreed on a specific response.
RESULTS: Most experts agreed that: (1) the current periprocedural/in-hospital stroke/death thresholds for performing a carotid intervention should be lowered from 6% to 4% in patients with SxCS and from 3% to 2% in patients with AsxCS; (2) the time threshold for a patient being considered "recently symptomatic" should be reduced from the current definition of "6 months" to 3 months or less; (3) 80% to 99% AsxCS carries a higher risk of stroke compared with 60% to 79% AsxCS; (4) factors beyond the grade of stenosis and symptoms should be added to the indications for revascularization in AsxCS patients (eg, plaque features of vulnerability and silent infarctions on brain computed tomography scans); and (5) shunting should be used selectively, rather than always or never. Consensus could not be reached on the remaining topics due to conflicting, inadequate, or controversial evidence.
CONCLUSIONS: The present international, multi-specialty expert-based Delphi Consensus document attempted to provide responses to several unanswered/unresolved issues. However, consensus could not be achieved on some topics, highlighting areas requiring future research.
The active ingredient in dexlansoprazole delayed-release capsules, a proton pump inhibitor, is 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2- pyridinyl]methyl]sulfinyl]-1H-benzimidazole Sesquihydrate, a compound that inhibits gastric acid secretion. Dexlansoprazole is the R-enantiomer of lansoprazole (a racemic mixture of the R\- and S-enantiomers). Dexlansoprazole sesquihydrate’s molecular formula is: C16H14F3N3O2S•1½ H2O, with a molecular weight of 396.39. Dexlansoprazole sesquihydrate has the following chemical structure:

Dexlansoprazole sesquihydrate is a white to brown color powder which melts with decomposition at 85.5°C. Dexlansoprazole sesquihydrate is freely soluble in N,N-dimethylformamide and practically insoluble in water.

Dexlansoprazole sesquihydrate is not stable when exposed to light. Dexlansoprazole sesquihydrate is not stable in alkaline or acidic conditions.

Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules. The capsules contain dexlansoprazole sesquihydrate in a single type of enteric-coated pellets [see Clinical Pharmacology (12.3)].

Dexlansoprazole delayed-release capsules are available in two dosage strengths: 30 and 60 mg, per capsule. Each capsule contains enteric-coated pellets consisting of dexlansoprazole sesquihydrate (active ingredient) and the following inactive ingredients: colloidal silicon dioxide, ethyl cellulose dispersion type B, hypromellose, methacrylic acid - ethyl acrylate copolymer (1:1) type A, mono- and di-glycerides, polysorbate 80, potassium hydroxide, povidone, sucrose, sugar spheres (corn starch and sucrose), talc and triethyl citrate. The components of the capsule shells include the following inactive ingredients: carrageenan, FD&C Blue No. 2, hypromellose, potassium chloride and titanium dioxide. The black imprinting ink contains black iron oxide, potassium hydroxide and shellac.
Sterile Water for Injection, USP is a sterile, nonpyrogenic water for injection intended only for dilution purposes. The pH is 5.4 (5.0 to 7.0). The Pharmacy Bulk Package is a sterile dosage form which contains multiple single doses for use only in a pharmacy bulk admixture program.

Sterile Water for Injection, USP contains no bacteriostat, antimicrobial agent or added buffer.

Sterile Water for Injection, USP may be classified as a sterile diluent and pharmaceutical vehicle.

Sterile Water for Injection, USP is chemically designated H2O.

The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions inside the plastic container also can leach out certain of its chemical components in very small amounts before the expiration period is attained. However, the safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers.
Considering the high consumption of and preference for traditional treatments among people and the lack of enough studies on the effectiveness of these treatments, we aimed to review articles on the use of traditional and complementary medicine, focusing on how they affect healing, debridement, and hypertrophic scars. In this study, we conducted the literature search in international databases PubMed, Google Scholar, Ovid, Scopus, Web of Science, and Cochrane Library, as well as Persian databases Scientific Information Database (SID), Magiran, Iranmedex, and IranDoc. Retrieved hits were reviewed by three authors for screening based on inclusion and exclusion criteria, and the screening process is expressed as Preferred Reporting Items for Systematic Reviews and Meta-Analyses framework flow chart. Twenty-two studies were included. The evaluated outcomes were wound healing in 19, pain control in 5, itching in 4, and scar appearance in 2 studies. All of the studies showed equal or improved effects compared to common treatments. Aloe vera, Centella asiatica, and Arnebia euchroma were the most common plants. We revealed that traditional medicine is beneficial in burn wound treatment. The diversity in ingredients that are used in traditional medicine brings up the need for further controlled prospective studies to evaluate the precise superiority of these treatments compared to standard care.
Embodiments disclosed herein provide compositions, methods, and uses for respiratory syncytial viruses (RSV) and immunogenic compositions thereof. Certain embodiments provide RSV having cleavage-resistant mutated attachment (G) glycoproteins. In some embodiments, the cleavage-resistant G protein mutants increase production of live attenuated RSV in host cells. Also provided are methods for amplifying RSV in host cells, wherein the amplified RSV has full length G protein. In certain embodiments, the amplified RSV having full length G protein is formulated into immunogenic compositions, including vaccines. Other embodiments provide methods for inducing an effective immune response against RSV infection in a subject.
To provide compositions for alleviating the symptoms of overactive bladder which can be taken easily for a long time in daily life.SOLUTION: The composition for alleviating the symptoms of overactive bladder contains a fermented product obtained by fermenting the squeezed juice or extract of Fagopyrum esculentum sprout, as an active ingredient. Preferably the fermented product contains 1 mg/100 g or more of quercetin and 0.1 mg/100 g or more of keracyanin in the solid content. Preferably the solid content also contains 10 mg/100 g or more of polyphenol. Also, preferably it has a pH ranging from pH 2.5 to 5. Further preferably the fermentation of the fermented product is caused by inoculating the juice or extract with a lactic acid bacterium. The composition for alleviating the symptoms of overactive bladder is suitably used for alleviating symptoms such as pollakiuria, urinary urgency, and urinary incontinence.SELECTED DRAWING: None
FIELD: medicine. SUBSTANCE: patient is prescribed to drink beverages to obtain washing-induced stools (WIS) samples. One obtains sufficient amount of cells exfoliated from the whole intestine useful for chemical and biological analyses. Test for collecting samples includes certain sequence of beverages and other substances for peroral intake which promote to obtain kept cells for medicinal diagnostics and enable to carry out cytological assay of WIS samples to recognize diseases of anterior and posterior intestine. To purify patient's digestive tract it is necessary to apply preliminary purgative solution, one stool, as minimum, caused by application of preliminary purgative solution should be collected, for the purpose to exfoliate and keep cells out of digestive tract one should apply final purgative solution. On finishing the procedure of preliminary purification patient could be prescribed to apply capsules providing remote action of preparations inside and containing purgative medicinal preparations. Test-kit is, also, supplied with devices to collect, seal and pack the WIS samples obtained for further analysis. EFFECT: higher efficiency. 13 cl, 5 dwg
ASMANEX HFA will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since mometasone furoate is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of ASMANEX HFA in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose.

Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with ASMANEX HFA should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when mometasone furoate is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of ASMANEX HFA should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids and for management of asthma symptoms.
The study universe will consist of adults of the ages 45-65 who have received a diagnosis of prediabetes and are registered at the Family Health Center No. 9. PREDIABE-TR mobile app usage (six months).
BACKGROUND: Short and rare episodes of atrial fibrillation (AF) are commonly detected using implanted devices (device-detected AF) in patients with prior stroke or transient ischemic attack (TIA). The effectiveness and safety of oral anticoagulation in patients with prior stroke or TIA and device-detected AF but with no ECG-documented AF is unclear.
METHODS AND RESULTS: This prespecified analysis of the NOAH-AFNET 6 (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes) trial with post hoc elements assessed the effect of oral anticoagulation in patients with device-detected AF with and without a prior stroke or TIA in the randomized, double-blind, double-dummy NOAH-AFNET 6 trial. Outcomes were stroke, systemic embolism, and cardiovascular death (primary outcome) and major bleeding and death (safety outcome). A prior stroke or TIA was found in 253 patients with device-detected AF randomized in the NOAH-AFNET 6 (mean age, 78 years; 36.4% women). There was no treatment interaction with prior stroke or TIA for any of the primary and secondary time-to-event outcomes. In patients with a prior stroke or TIA, 14 out of 122 patients experienced a primary outcome event with anticoagulation (5.7% per patient-year). Without anticoagulation, there were 16 out of 131 patients with an event (6.3% per patient-year). The rate of stroke was lower than expected (anticoagulation: 4 out of 122 [1.6% per patient-year]; no anticoagulation: 6 out of 131 [2.3% per patient-year]). Numerically, there were more major bleeding events with anticoagulation in patients with prior stroke or TIA (8 out of 122 patients) than without anticoagulation (2 out of 131 patients).
CONCLUSIONS: Anticoagulation appears to have ambiguous effects in patients with device-detected AF and a prior stroke or TIA in this hypothesis-generating analysis of the NOAH-AFNET 6 in the absence of ECG-documented AF, partially due to a low rate of stroke without anticoagulation.
The placebo will be delivered intramuscularly into the deltoid muscle at Days 0, 30, and between 60 and 90. Each dose will consist of 0.4mL normal saline.
PCT No. PCT/US85/00109 Sec. 371 Date Sep. 4, 1986 Sec. 102(e) Date Sep. 4, 1986 PCT Filed Jan. 22, 1985 PCT Pub. No. WO86/04239 PCT Pub. Date Jul. 31, 1986.A series of novel, macrocyclic polyether compounds. The macrocycles have a 21-membered ring, containing six oxygen atoms, and they have a carboxy group (or a salt thereof) directed towards the interior of the ring. Administration of the compounds of the invention to ruminant animals (e.g. cattle and sheep) modifies their digestive fermentation processes such that the volatile fatty acids produced in the rumen contain a higher proportion of propionates rather than acetates, thereby increasing the efficiency of feed utilization in said ruminant animals. Additionally, the compounds of the invention show antibacterial activity in vitro against certain gram-positive microorganisms.
PROBLEM TO BE SOLVED: To obtain a novel polypeptide, composed of specific amino acid sequences, having activities of, e.g. hematopoietic cell controlling, actibin/inhibin, chemotaxis/chemical mobility and coagulation, and useful for, e.g. prophylaxis and treatment of various diseases. SOLUTION: This polypeptide, homologude thereof, fragment thereof or homologue of the fragment is a novel one composed of substantially pure amino acid sequences, e.g. shown by formulae I to III. It exhibits various functions, e.g. those of hematopoietic cell controlling, histogenesis/historeactivation, actibin/ inhibin, chemotaxis/chemical mobility, coagulation/clot and receptor/ligand, and useful for, e.g. prophylaxis and treatment of various diseases This polypeptide is obtained by integrating cDNA, screened by the yeast signal sequence trapping method with the acid of a cDNA library prepared from a human adjust brain tissue or the like, into an expression vector, genetically transducing the cDNA in a host cell, and culturing the host cell.
Disclosed in the present invention is a gel formulation oil-in-water-type cosmetic material composition comprising: a fatty acid; hydrocarbon-based oil; an emulsifier having HLB of 3 to 6; an emulsifier having HLB of 10 to 18; and oil absorption powder. The cosmetic material composition has phase transition characteristics from a gel phase to a liquid phase when being applied to skin. Specifically, the gel formulation oil-in-water-type cosmetic material composition according to the present invention simultaneously contains a w/o-type emulsifier having HLB of 3 to 6 and an o/w-type emulsifier having HLB of 10 to 18. Thus, due to rapid phase transition properties to a liquid from a gel formulation when the composition is applied to skin, strong adhesion senses and dry and soft finishing senses are ensured after water is volatilized, and the sense of use is excellent. In addition, the gel formulation oil-in-water-type cosmetic material composition according to the present invention has good spreading properties due to a high viscosity gel formulation, and an oil component is stably emulsified. Thus, skin moisturizing senses are also excellent.
The concept of "oligometastatic" disease suggests the presence of intermediate states between localized disease and widespread metastases, which may be potentially treatable with curative therapeutic strategies. Metastases local therapy (MLT) can be accomplished through various techniques such as stereotactic ablative radiotherapy (SABR), radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, or surgical metastasectomy. The incorporation of MLT in the multidisciplinary treatment of patients with metastatic sarcoma is complex. Retrospective studies support consideration of MLT for selected patients based on factors such as patient condition, disease biology, histologic type, and disease burden. Decisions regarding type and timing of MLT should be made after multidisciplinary discussion including radiation oncologists, surgical and orthopedic oncologists, medical oncologists, and interventional radiology to explore all options before treatment decsions. All MLT techniques have advantages and disadvantages and should be performed in centers specialized in the care of complex oncology patients where various options can be explored concurrently or sequentially for each patient. Future studies evaluating quality of life and patient-reported outcomes are necessary to adequately align patient goals and optimal outcomes. This article reviews the medical scenarios that may benefit the use of MLT, evaluates the distinct advantages and disadvantages associated with these various techniques, and analyzes the findings from pivotal series to provide a comprehensive understanding of its role in clinical practice.
The invention relates to a traditional Chinese medicine for treating breast hyperplasia, especially to a traditional Chinese medicine composition for treating breast hyperplasia. In the formula of the traditional Chinese medicine composition, radix codonopsis has effects of warming the kidney, dispelling cold and relieving pain; the kidney is the origin of congenital constitution, and kidney qi is sufficient enough to nourish the liver so as to further strengthen body resistance and eliminate evil; herba aristolochiae has effects of soothing the liver, promoting qi circulation and removing obstruction in the collateral; Poria cocos has effects of clearing damp and promoting dieresis and promoting circulation of body fluid of liver; and Zanthoxylum dissitum Hemsl. has effects of promoting blood flow to remove stasis decoction and regulating qi to alleviate pain. By compatibility of the above four drugs, effects of soothing liver, regulating qi, promote blood circulation to remove blood stasis, promoting circulation of body fluid of liver and eliminating breast lesions can be achieved. With assistance of radix bupleuri and white peony root, effects of coursing the liver, calming the liver, nourishing liver and relieving pain can be enhanced. Angelica sinensis has effects of enriching the blood, invigorating the circulation of blood and removing blood stasis. Zaocys dhumnade and caulis spatholobi have effects of dispersing stagnation, dredging the collaterals and removing blood stasis. Artemisia apiacea and prunella vulgaris have effects of clearing away deficiency fire, eliminating stagnation and removing swelling so as to promote granulation and relieve pain. Licorice has effects of relaxing spasm, relieving pain and moderating the property of herbs.
PURPOSE: The aim of this study is to critically evaluate the existing body of evidence regarding the efficacy of Retzius-sparing radical prostatectomy (RS-RARP) in achieving improved functional outcomes. Moreover, we explored possible strategies to further optimize functional outcomes.
METHODS: Following PRISMA guidelines, a systematic review (PROSPERO ID CRD42024539915) was performed on 9th September 2023 on PubMed, Scopus, and Web of Science. Only original articles in the English language reporting functional outcomes after RS-RARP were included.
RESULTS: Overall, the search string yielded 99 results on PubMed, 122 on Scopus, and 120 on Web Of Science. After duplicate exclusion, initial screening and eligibility evaluation, a total of 47 studies were included in the qualitative analysis, corresponding to a cohort of 13.196 patients. All studies reported continence recovery. RS-RARP appeared to achieve better and faster continence recovery compared to S-RARP. However, it should be noted that continence definition was heterogeneous and not based on validated condition-specific questionnaires. Seven (15%) studies provided for any sort of rehabilitation for urinary incontinence after RS-RARP. 22 studies analyzed potency recovery rates, showing no difference between RS-RARP and S-RARP. The evaluation of this outcome poses a great challenge due to the lack of standardized assessment tools and reporting methods. Only two studies reported on the consistent use of post-operative PDE5i as penile rehabilitation.
CONCLUSIONS: The current review highlights the satisfactory functional results of Retzius-sparing robot assisted radical prostatectomy, which holds true irrespective of disease stage and prostate volume, with promising results even in patients previously treated for BPH or in the salvage setting. How can we optimize those results? The answer does not probably lie in further refinement of the surgical technique, but in giving greater attention to patient counselling and rehabilitation strategies in order to minimize regret and maximize satisfaction.